Companies · Pharmaceuticals

Affinimark Technologies Inc

NEW HAVEN · Pharmaceuticals

Diligence memoA one-page analyst read on Affinimark Technologies Inc — recommendation, valuation, rhythm, risks.
$2.4M
Total raised · real
2
Rounds
1.0×
Latest step-up
Top 71%
Sector rank · raised
Seed
Latest stage · inferred · Fri Feb 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Affinimark Technologies Inc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.98× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era.
  • Within the normal band (98% of peer median) for its niche.
Dormant
  • Last raise 10.4 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Affinimark Technologies Inc is one of 1613 Pharmaceuticals companies tracked from NEW HAVEN. By capital raised it ranks in the long tail (ahead of 30% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2010-09-27 Raised $822K (real) Modeled valuation $39M (est)$822K$39MPre-Seed2010Seed · 2016-02-12 Raised $1.6M (real) Modeled valuation $59M (est)$1.6M$59MSeed2016Seed · 2016-02-12 Raised $1.6M (real) Modeled valuation $59M (est)$1.6M$59MSeed2016+$1.6M+$1.6MCumulative $3.9M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$822K · 2010
Seed$1.6M · 2016
Seed extension$1.6M · 2016

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$59.0M
Base estimate est.
$1.2M
Conservative case
$462.6M
Upside case
$7.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $38.9M · 2010-09-272010Seed · modeled $59.0M · 2016-02-12Seed · modeled $59.0M · 2016-02-122016
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
10.4 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
32 mo
Avg between rounds
$441K/yr
Capital velocity
15.8 yr
On record since
2010
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.4M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.9× of median
This company$1.6M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.8× of median
This company$59.0M
Sector median$76.1M

Raised more than 30% of sector peers (real $). Modeled value above 46% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #38 of 71.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Chase Therapeutics Corp · Seed Raised $5.3M · modeled $152.2M (est)Acura Pharmaceuticals, Inc · Seed Raised $4.0M · modeled $152.2M (est)Paragon Biosciences Skyline Capital, LLC · Seed Raised $4.0M · modeled $150.9M (est)Phoenix PharmaLabs Inc · Seed Raised $3.5M · modeled $133.1M (est)Saghmos Therapeutics, Inc. · Seed Raised $3.5M · modeled $133.1M (est)Immucell Corp /De/ · Seed Raised $3.5M · modeled $131.8M (est)Madrigal Pharmaceuticals, Inc. · Seed Raised $3.4M · modeled $128.4M (est)Hydropothecary Corp · Seed Raised $3.3M · modeled $124.6M (est)SapVax, LLC · Seed Raised $3.3M · modeled $123.6M (est)VersaPeutics, Inc. · Seed Raised $3.8M · modeled $121.7M (est)Westwood Life Sciences, Llc · Seed Raised $3.1M · modeled $116.3M (est)Har-Kcy, Llc · Seed Raised $3.0M · modeled $114.3M (est)Affinimark Technologies Inc (this company) Raised $2.4M · modeled $59.0M (est)Affinimark Technologies Inc
CompanyStageRaised · realValue · estvs peer med.
Chase Therapeutics CorpSeed$5.3M$152.2M2.52×
Acura Pharmaceuticals, IncSeed$4.0M$152.2M2.52×
Paragon Biosciences Skyline Capital, LLCSeed$4.0M$150.9M2.50×
Phoenix PharmaLabs IncSeed$3.5M$133.1M2.21×
Saghmos Therapeutics, Inc.Seed$3.5M$133.1M2.21×
Immucell Corp /De/Seed$3.5M$131.8M2.19×
Madrigal Pharmaceuticals, Inc.Seed$3.4M$128.4M2.13×
Hydropothecary CorpSeed$3.3M$124.6M2.07×
SapVax, LLCSeed$3.3M$123.6M2.05×
VersaPeutics, Inc.Seed$3.8M$121.7M2.02×
Westwood Life Sciences, LlcSeed$3.1M$116.3M1.93×
Har-Kcy, LlcSeed$3.0M$114.3M1.90×
Affinimark Technologies Inc this companySeed$2.4M$59.0M0.98×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$822K2010-09-27$4.6M$38.9M90%
Seed$1.6M2016-02-12$7.8M$59.0M90%
Seed$1.6M2016-02-12$7.8M$59.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$822K2010-09-27
    • First recorded raise — entered as Pre-Seed.
  2. Seed$1.6M2016-02-12
    • Raised again after 65 mo — slower than the ~13 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
  3. Seed$1.6M2016-02-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
Intelligence
2018 ~Q4
Modeled next raise · ~32mo cadence
$1.6M
Modeled next size est.range $1.6M$2.5M
1.0×
Last step-up
$441K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
KEVIN CROWLEY8 other2016-02
Harry H Penner, Jr.5 other2010-09
Larry H. Dillaha1 other2016-02
Patrick H. Fourteau1 other2016-02
Kevin H Crowley2010-09
KONSTANTINE H. DRAKONAKIS2016-02
MICHAEL H. MILLIGAN2016-02
VINCENT H. PIERIBONE2010-09
Registry & provenance

Affinimark Technologies Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1429101
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
New Haven Pharmaceuticals, Inc.PharmaceuticalsSeries A$18.9M$18.7Mnetwork3 shared operators · same sector
ARYx Therapeutics, Inc.PharmaceuticalsSeed$2.4M$76.6Msame sector · same stage
Ammonett Pharma LLCPharmaceuticalsSeed$2.4M$90.7Msame sector · same stage
IGF Oncology, LLCPharmaceuticalsSeed$2.4M$89.7Msame sector · same stage
Raptor Pharmaceuticals Corp.PharmaceuticalsSeed$2.4M$90.8Msame sector · same stage
Groupe Athena, Inc.PharmaceuticalsSeed$2.4M$89.6Msame sector · same stage
Designmedix IncPharmaceuticalsSeed$2.4M$24.8Msame sector · same stage
Madison Vaccines IncPharmaceuticalsSeed$2.4M$91.5Msame sector · same stage
Frequently asked
How much funding has Affinimark Technologies Inc raised?
Affinimark Technologies Inc has raised approximately $2.4M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Affinimark Technologies Inc's estimated valuation?
Provath's modeled valuation for Affinimark Technologies Inc is approximately $59.0M (modeled range $1.2M–$462.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Affinimark Technologies Inc at?
Affinimark Technologies Inc's latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Feb 12.
What does Affinimark Technologies Inc do and where is it based?
Affinimark Technologies Inc operates in the Pharmaceuticals sector, based in NEW HAVEN.
Explore related

See where Affinimark Technologies Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Affinimark Technologies Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.